Informatic Tools and Approaches in Postmarketing Pharmacovigilance Used by FDA

A. P. Fletcher. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J. R. Soc. Med. 84(6):341–344 (1991).

V. Pinkston, and E. J. Swain. Management of adverse drug reaction and adverse event data through collection storage and retrieval. In M. D. B Stephens, and P. A. Routledge (eds.), Detection of New Adverse Drug Reactions: Macmillan References LTD., London, UK, 1999, pp. 282.

FDA Office of Surveillance and Epidemiology, unpublished data, 2006.

A. Szarfman, S. G. Machado, and R. T. O’Neill. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug. Saf. 25(6):381–392 (2002).

M. Hauben, and X. Zhou. Quantitative methods in pharmacovigilance: focus on signal detection. Drug. Saf. 26(3):159–186 (2003).

MSSO website. URL http://www.meddramsso.com/MSSOWeb/index.htm.

S. R. Ahmad. Spontaneous reporting in the United States. In B. L. Strom (ed.), Pharmacoepidemiology: Wiley and Sons, West Sussex, England, 2005, pp. 136–159.

H. S. Nelson, S. T. Weiss, E. R. Bleecker, S. W. Yancey, and P. M. Dorinsky. SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 129(1):15–26 (2006).

L. La Grenade, L. Lee, J. Weaver, R. Bonnel, C. Karwoski, L. Governale, and A. Brinker. Comparison of reporting of Stevens–Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug. Saf. 28(10):917–924 (2005).

B. L. Strom. Study designs available for pharmacopeidemiology studies. In B. L. Strom (ed.), Pharmacoepidemiology: Wiley and Sons, West Sussex, England, 2005, pp. 17–28.

L. Gordis. Epidemiology. W.B. Saunders Company, Philadelphia, 1996.

K. J. Rothman, and S. Greenland. Modern epidemiology, 2nd ed. Lippincott-Raven, Philadelphia, PA, 1998.

B. L. Strom. Study overview of automated databases in pharmacoepidemiology. In B. L. Strom (ed.), Pharmacoepidemiology: Wiley and Sons, West Sussex, England, 2005, pp. 219–222.

S. Hennessy. Use of health care databases in pharmacoepidemiology. Basic Clin. Pharmacol. Toxicol. 98:311–313 (2006).

D. S. Budnitz, D. A. Pollcok, K. N. Weidenbach, A. B. Mendelsohn, T. J. Schroeder, and J. L. Annest. National surveillance of emergency department visits for outpatient adverse drug events. JAMA296:1858–1866 (2006).

Natalizumab Advisory Committee, March 2006: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4208S1-Slide-Index.htm, last accessed July 9, 2007.

T. A. Yousry, M. Habil, E. O. Major, C. Ryschkewitsch, G. Fajhle, S. Fiscer, J. Hou, B. Curfman, K. Miszkiel, N. Mueller-Lenke, E. Sanches, F. Barkhof, E. Radue, H. R. Jager, and D. B. Clifford. Evaluation of patients treated with Natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354:924–933 (2006).

Natalizumab information: http://www.fda.gov/cder/drug/infopage/natalizumab/default.htm, last accessed August 10, 2007.

J. H. Hoofnagle. Drug-induced liver injury network (DILIN). Hepatology 40:773 (2004).

N. Chalasani, R. Fontana, P. B. Watkins, H. L. Bonkovsky, T. Davern, J. Serrano, and J. Rochan. Drug-induced liver injury network (DILIN) prospective study initial results. Am. J. Gastroenterol. 101:S168 (2006).

T. A. Hammad, T. Laughren, and J. Racoosin. Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 63:332–339 (2006).

Anti-depressant December 2006 advisory committee http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4272s1-00-index.htm; last accessed July 9, 2007.

Future of Drug Safety; FDA’s Specific Safety Initiatives; upgrading methods of benefit and risk analysis and risk management: www.fda.gov/oc/reports/iom013007.html, page 37, last accessed July 9, 2009.